Last reviewed · How we verify

NCT06837610: Inverte T trab

Inverted T Trabeculectomy Primary Congenital Glaucoma

Active, enrolled NA Last updated 20 February 2025
What this trial tests

NA trial testing Inverted T trabeculectomy in Glaucoma, Congenital, Surgical Treatment in 25 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2023
Primary endpoint
1 July 2024
1 March 2025

Quick facts

Lead sponsorBenha University
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment25
Start date1 January 2023
Primary completion1 July 2024
Estimated completion1 March 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Benha University

Who can join

Under 12 Months, any sex, with Glaucoma, Congenital, Surgical Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the safety and efficacy of novel Inverted T trabeculectomy in Primary Congenital Glaucoma (PCG). It enrolled 50 eyes of 25 children with PCG. The mean age at the time of surgery was 12±11 months, and the mean presenting IOP was 40±4 mmHg. Patients with previous intra-ocular or conjunctival surgery, those who had significant ocular trauma, and patients with congenital glaucoma associated with ocular anomalies diseases were excluded from the study. All patients had Inverted T trabeculectomy under general anesthesia. The IOP in the operated eyes was followed up for 36 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Benha University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing